Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab for Early Stage GEA
NCT04089904Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Oct 2019
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by University of Chicago. Started Oct 2019; status: terminated.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT04089904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089904.